Printer Friendly

-Norwegian Bionor Pharma to start trial on HIV vaccine and cancer therapy.

NORDIC BUSINESS REPORT-August 25, 2011--Norwegian Bionor Pharma to start trial on HIV vaccine and cancer therapy(C)2011 M2 COMMUNICATIONS

25 August 2011 - Norwegian company Bionor Pharma ASA (OSL:BIONOR) said today it would start a study to examine the ability of its therapeutic HIV vaccine candidate Vacc-4x to improve the immune defence in combination with cancer treatment Revlimid.

The study, expected to cost around USD1.4m, will include 24 HIV-patients who fail to regain a healthy immune defence despite that their viral load is controlled via antiretroviral (ART) therapy.

It will be placebo-controlled and double-blind.

The trial will be performed in Germany and will be preceded by an open-label dose finding study to select the most appropriate Revlimid dose.

Treatment and observation will last for 26 weeks, starting in September. Results from the study are expected in the first half of 2013.

(EUR1 = USD1.4)

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Date:Aug 25, 2011
Previous Article:-Norwegian Solstad Offshore's Q2 net loss narrows.
Next Article:-Novo Nordisk to expand head office in DKK1bn construction.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters